4.8.3Segment

Diabetes & Metabolic Devices

Manufacturers of continuous glucose monitors, insulin pumps, and metabolic disease management devices.

5
Verticals

Overview

Diabetes & Metabolic Devices covers manufacturers of continuous glucose monitors (CGMs), insulin pumps, and metabolic-disease management devices. It is one of the fastest-growing medtech categories, driven by the explosive adoption of CGMs (Dexcom, Abbott Libre) and automated insulin delivery (Insulet, Tandem, Medtronic).

CGM expansion beyond type 1 into type 2 and even non-diabetic wellness, plus the interplay with GLP-1 obesity drugs, are reshaping the category's growth. It is innovation- and consumable-driven, with recurring sensor and supply revenue, and is a high-growth focus for both strategics and investors.

Market snapshot

FragmentationConsolidatedEstimate

Within electromedical and instrument manufacturing (NAICS 334510/339112); the Census Bureau does not split out diabetes devices, so the segment is not separately sized.

Business model & economics

Revenue model

Devices plus high-margin recurring sensors and supplies

Key economics

Recurring revenue
High

recurring CGM sensors and pump supplies

EBITDA margin
Strong

recurring-consumable economics

Capex intensity
High

Characteristics

  • Among the fastest-growing medtech categories.
  • CGM adoption expanding into type 2 and wellness.
  • Recurring sensor-and-supply razor-and-blade model.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineNew JerseyNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandMassachusettsMinnesotaCaliforniaUtah

Diabetes and metabolic-device manufacturing clusters in the major medtech hubs of Minnesota, Massachusetts, Utah, and California, home to the sector's leading device makers.

MinnesotaMassachusettsUtahCalifornia

U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 334510/339112. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Diabetes-device strategics
  • Diversified medtech platforms
  • VC-backed innovators

What’s driving deals

  • CGM and automated-insulin-delivery growth.
  • Expansion into type 2 and metabolic wellness.
  • Recurring-consumable economics.

Verticals in this segment

Find Diabetes & Metabolic Devices acquisition targets

Search Acquisera’s index for companies classified under Diabetes & Metabolic Devices (4.8.3) and build a targeted deal pipeline.

Search companies